Country
United States
Cancer incidence and mortality for United States as published by the source registry: per site group, per year and sex, with age-standardized rates where the source provides them. Population statistics describe groups, never individuals.
- ISO 3166-1
- USA · US
- WHO region
- WHO Region of the Americas
- Population
- not seeded — CancerIndex shows only rates and counts published by the source
- Years covered
- 1999–2024
- Cancer entities
- 36
- Estimate types
- observed
Summary
2015 · both sexes · all ages
Totals across all cancer sites are shown only when the source publishes an all-sites row. Otherwise the per-site figures below stand on their own; CancerIndex never sums site groups (definitions overlap between sources).
- Deathshighest site group:Malignant Lung Neoplasm153,718countcdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
- New caseshighest site group:Malignant Breast Neoplasm251,269countcdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
- Mortality rate (age-standardized)highest site group:Malignant Lung Neoplasm41.2per 100,000cdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
- Incidence rate (age-standardized)highest site group:Malignant Breast Neoplasm68.7per 100,000cdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
No all-sites total in source for this scope — per-site figures below; no national total is computed.
Top cancers
By deaths
2015 · both sexes · all ages · 31 site groups
| # | Cancer | Deaths (count) | 95% CI | Type | Rank in scope | Site definition | Source |
|---|---|---|---|---|---|---|---|
| 1 | Malignant Lung NeoplasmCancer | 153,718 | — | observed | #1 of 31 | USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349) | cdc-uscsObserved |
| 2 | Malignant Colon NeoplasmCancer | 42,361 | — | observed | #2 of 31 | USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260) | cdc-uscsObserved |
| 3 | Malignant Breast NeoplasmCancer Family | 41,986 | — | observed | #3 of 31 | USCS "Male and Female Breast" (ICD-10 C50; ICD-O-3 C500-C509) | cdc-uscsObserved |
| 4 | Malignant Pancreatic NeoplasmCancer | 41,615 | — | observed | #4 of 31 | USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259) | cdc-uscsObserved |
| 5 | Malignant Prostate NeoplasmCancer | 28,848 | — | observed | #5 of 31 | USCS "Prostate" (ICD-10 C61; ICD-O-3 C619) | cdc-uscsObserved |
| 6 | Malignant Liver NeoplasmCancer | 25,760 | — | observed | #6 of 31 | USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221) | cdc-uscsObserved |
| 7 | LeukemiaCancer Family | 22,847 | — | observed | #7 of 31 | USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode) | cdc-uscsObserved |
| 8 | Non-Hodgkin LymphomaHematologic Malignancy | 20,154 | — | observed | #8 of 31 | USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood)) | cdc-uscsObserved |
| 9 | Malignant Central Nervous System NeoplasmCancer | 16,268 | — | observed | #9 of 31 | USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729) | cdc-uscsObserved |
| 10 | Malignant Bladder NeoplasmCancer | 16,254 | — | observed | #10 of 31 | USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679) | cdc-uscsObserved |
| 11 | Malignant Esophageal NeoplasmCancer | 15,211 | — | observed | #11 of 31 | USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159) | cdc-uscsObserved |
| 12 | Malignant Kidney NeoplasmCancer | 14,448 | — | observed | #12 of 31 | USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659) | cdc-uscsObserved |
| 13 | Malignant Ovarian NeoplasmCancer | 13,920 | — | observed | #13 of 31 | USCS "Ovary" (ICD-10 C56; ICD-O-3 C569) | cdc-uscsObserved |
| 14 | Multiple MyelomaHematologic Malignancy | 12,231 | — | observed | #14 of 31 | USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734) | cdc-uscsObserved |
| 15 | Malignant Gastric NeoplasmCancer | 11,330 | — | observed | #15 of 31 | USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169) | cdc-uscsObserved |
| 16 | Malignant Rectal NeoplasmCancer | 10,035 | — | observed | #16 of 31 | USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209) | cdc-uscsObserved |
| 17 | Cutaneous MelanomaCancer | 8,885 | — | observed | #17 of 31 | USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790) | cdc-uscsObserved |
| 18 | Malignant Uterine Corpus NeoplasmCancer | 4,350 | — | observed | #18 of 31 | USCS "Corpus" (ICD-10 C54; ICD-O-3 C540-C549) | cdc-uscsObserved |
| 19 | Malignant Cervical NeoplasmCancer | 4,175 | — | observed | #19 of 31 | USCS "Cervix" (ICD-10 C53; ICD-O-3 C530-C539) | cdc-uscsObserved |
| 20 | Malignant Laryngeal NeoplasmCancer | 3,763 | — | observed | #20 of 31 | USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329) | cdc-uscsObserved |
| 21 | Malignant MesotheliomaCancer Family | 2,404 | — | observed | #21 of 31 | USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site)) | cdc-uscsObserved |
| 22 | Malignant Thyroid Gland NeoplasmCancer | 1,894 | — | observed | #22 of 31 | USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739) | cdc-uscsObserved |
| 23 | Malignant Vulvar NeoplasmCancer | 1,127 | — | observed | #23 of 31 | USCS "Vulva" (ICD-10 C51; ICD-O-3 C510-C519) | cdc-uscsObserved |
| 24 | Hodgkin LymphomaHematologic Malignancy | 1,120 | — | observed | #24 of 31 | USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal)) | cdc-uscsObserved |
| 25 | Malignant Anal NeoplasmCancer | 1,014 | — | observed | #25 of 31 | USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218) | cdc-uscsObserved |
| 26 | Malignant Salivary Gland NeoplasmCancer | 993 | — | observed | #26 of 31 | USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089) | cdc-uscsObserved |
| 27 | Malignant Nasopharyngeal NeoplasmCancer | 709 | — | observed | #27 of 31 | USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119) | cdc-uscsObserved |
| 28 | Malignant Vaginal NeoplasmCancer | 438 | — | observed | #28 of 31 | USCS "Vagina" (ICD-10 C52; ICD-O-3 C529) | cdc-uscsObserved |
| 29 | Malignant Testicular NeoplasmCancer | 374 | — | observed | #29 of 31 | USCS "Testis" (ICD-10 C62; ICD-O-3 C620-C629) | cdc-uscsObserved |
| 30 | Malignant Hypopharyngeal NeoplasmCancer | 369 | — | observed | #30 of 31 | USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139) | cdc-uscsObserved |
| 31 | Malignant Penile NeoplasmCancer | 301 | — | observed | #31 of 31 | USCS "Penis" (ICD-10 C60; ICD-O-3 C600-C609) | cdc-uscsObserved |
cdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Top cancers
By new cases
2015 · both sexes · all ages · 32 site groups
| # | Cancer | New cases (count) | 95% CI | Type | Rank in scope | Site definition | Source |
|---|---|---|---|---|---|---|---|
| 1 | Malignant Breast NeoplasmCancer Family | 251,269 | — | observed | #1 of 32 | USCS "Male and Female Breast" (ICD-10 C50; ICD-O-3 C500-C509) | cdc-uscsObserved |
| 2 | Malignant Lung NeoplasmCancer | 225,781 | — | observed | #2 of 32 | USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349) | cdc-uscsObserved |
| 3 | Malignant Prostate NeoplasmCancer | 199,379 | — | observed | #3 of 32 | USCS "Prostate" (ICD-10 C61; ICD-O-3 C619) | cdc-uscsObserved |
| 4 | Malignant Colon NeoplasmCancer | 102,952 | — | observed | #4 of 32 | USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260) | cdc-uscsObserved |
| 5 | Cutaneous MelanomaCancer | 83,888 | — | observed | #5 of 32 | USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790) | cdc-uscsObserved |
| 6 | Malignant Bladder NeoplasmCancer | 76,826 | — | observed | #6 of 32 | USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679) | cdc-uscsObserved |
| 7 | Non-Hodgkin LymphomaHematologic Malignancy | 72,624 | — | observed | #7 of 32 | USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood)) | cdc-uscsObserved |
| 8 | Malignant Kidney NeoplasmCancer | 64,636 | — | observed | #8 of 32 | USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659) | cdc-uscsObserved |
| 9 | LeukemiaCancer Family | 54,865 | — | observed | #9 of 32 | USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode) | cdc-uscsObserved |
| 10 | Malignant Uterine Corpus NeoplasmCancer | 53,727 | — | observed | #10 of 32 | USCS "Corpus" (ICD-10 C54; ICD-O-3 C540-C549) | cdc-uscsObserved |
| 11 | Malignant Thyroid Gland NeoplasmCancer | 50,099 | — | observed | #11 of 32 | USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739) | cdc-uscsObserved |
| 12 | Malignant Pancreatic NeoplasmCancer | 49,708 | — | observed | #12 of 32 | USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259) | cdc-uscsObserved |
| 13 | Malignant Rectal NeoplasmCancer | 42,141 | — | observed | #13 of 32 | USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209) | cdc-uscsObserved |
| 14 | Malignant Liver NeoplasmCancer | 34,864 | — | observed | #14 of 32 | USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221) | cdc-uscsObserved |
| 15 | Multiple MyelomaHematologic Malignancy | 27,373 | — | observed | #15 of 32 | USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734) | cdc-uscsObserved |
| 16 | Malignant Gastric NeoplasmCancer | 24,473 | — | observed | #16 of 32 | USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169) | cdc-uscsObserved |
| 17 | Malignant Central Nervous System NeoplasmCancer | 23,165 | — | observed | #17 of 32 | USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729) | cdc-uscsObserved |
| 18 | Malignant Ovarian NeoplasmCancer | 22,238 | — | observed | #18 of 32 | USCS "Ovary" (ICD-10 C56; ICD-O-3 C569) | cdc-uscsObserved |
| 19 | Malignant Esophageal NeoplasmCancer | 17,720 | — | observed | #19 of 32 | USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159) | cdc-uscsObserved |
| 20 | Malignant Cervical NeoplasmCancer | 13,210 | — | observed | #20 of 32 | USCS "Cervix" (ICD-10 C53; ICD-O-3 C530-C539) | cdc-uscsObserved |
| 21 | Malignant Laryngeal NeoplasmCancer | 12,684 | — | observed | #21 of 32 | USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329) | cdc-uscsObserved |
| 22 | Malignant Testicular NeoplasmCancer | 8,855 | — | observed | #22 of 32 | USCS "Testis" (ICD-10 C62; ICD-O-3 C620-C629) | cdc-uscsObserved |
| 23 | Hodgkin LymphomaHematologic Malignancy | 8,769 | — | observed | #23 of 32 | USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal)) | cdc-uscsObserved |
| 24 | Malignant Anal NeoplasmCancer | 7,383 | — | observed | #24 of 32 | USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218) | cdc-uscsObserved |
| 25 | Malignant Vulvar NeoplasmCancer | 5,246 | — | observed | #25 of 32 | USCS "Vulva" (ICD-10 C51; ICD-O-3 C510-C519) | cdc-uscsObserved |
| 26 | Malignant Salivary Gland NeoplasmCancer | 4,804 | — | observed | #26 of 32 | USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089) | cdc-uscsObserved |
| 27 | Malignant MesotheliomaCancer Family | 3,314 | — | observed | #27 of 32 | USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site)) | cdc-uscsObserved |
| 28 | Malignant Hypopharyngeal NeoplasmCancer | 2,452 | — | observed | #28 of 32 | USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139) | cdc-uscsObserved |
| 29 | Malignant Nasopharyngeal NeoplasmCancer | 1,958 | — | observed | #29 of 32 | USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119) | cdc-uscsObserved |
| 30 | Malignant Penile NeoplasmCancer | 1,426 | — | observed | #30 of 32 | USCS "Penis" (ICD-10 C60; ICD-O-3 C600-C609) | cdc-uscsObserved |
| 31 | Malignant Vaginal NeoplasmCancer | 1,288 | — | observed | #31 of 32 | USCS "Vagina" (ICD-10 C52; ICD-O-3 C529) | cdc-uscsObserved |
| 32 | Kaposi SarcomaCancer | 1,223 | — | observed | #32 of 32 | USCS "Kaposi Sarcoma" (ICD-10 C46; ICD-O-3 histology 9140 (any site)) | cdc-uscsObserved |
cdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Top cancers
By mortality rate (age-standardized)
2015 · both sexes · all ages · 23 site groups · 2000 U.S. standard population (19 age groups)
| # | Cancer | Mortality rate (age-standardized) (per 100,000) | 95% CI | Type | Rank in scope | Site definition | Source |
|---|---|---|---|---|---|---|---|
| 1 | Malignant Lung NeoplasmCancer | 41.2 | 41–41.4 | observed | #1 of 23 | USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349) | cdc-uscsObserved |
| 2 | Malignant Colon NeoplasmCancer | 11.5 | 11.4–11.6 | observed | #2 of 23 | USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260) | cdc-uscsObserved |
| 3 | Malignant Breast NeoplasmCancer Family | 11.4 | 11.3–11.5 | observed | #3 of 23 | USCS "Male and Female Breast" (ICD-10 C50; ICD-O-3 C500-C509) | cdc-uscsObserved |
| 4 | Malignant Pancreatic NeoplasmCancer | 11.2 | 11–11.3 | observed | #4 of 23 | USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259) | cdc-uscsObserved |
| 5 | Malignant Liver NeoplasmCancer | 6.7 | 6.6–6.7 | observed | #5 of 23 | USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221) | cdc-uscsObserved |
| 6 | LeukemiaCancer Family | 6.4 | 6.3–6.5 | observed | #6 of 23 | USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode) | cdc-uscsObserved |
| 7 | Non-Hodgkin LymphomaHematologic Malignancy | 5.6 | 5.5–5.6 | observed | #7 of 23 | USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood)) | cdc-uscsObserved |
| 8 | Malignant Bladder NeoplasmCancer | 4.5 | 4.4–4.5 | observed | #8 of 23 | USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679) | cdc-uscsObserved |
| 9 | Malignant Central Nervous System NeoplasmCancer | 4.5 | 4.4–4.5 | observed | #8 of 23 | USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729) | cdc-uscsObserved |
| 10 | Malignant Esophageal NeoplasmCancer | 4 | 3.9–4.1 | observed | #10 of 23 | USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159) | cdc-uscsObserved |
| 11 | Malignant Kidney NeoplasmCancer | 3.9 | 3.8–3.9 | observed | #11 of 23 | USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659) | cdc-uscsObserved |
| 12 | Multiple MyelomaHematologic Malignancy | 3.4 | 3.3–3.4 | observed | #12 of 23 | USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734) | cdc-uscsObserved |
| 13 | Malignant Gastric NeoplasmCancer | 3.1 | 3.1–3.2 | observed | #13 of 23 | USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169) | cdc-uscsObserved |
| 14 | Malignant Rectal NeoplasmCancer | 2.7 | 2.6–2.8 | observed | #14 of 23 | USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209) | cdc-uscsObserved |
| 15 | Cutaneous MelanomaCancer | 2.4 | 2.4–2.5 | observed | #15 of 23 | USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790) | cdc-uscsObserved |
| 16 | Malignant Laryngeal NeoplasmCancer | 1 | 0.9–1 | observed | #16 of 23 | USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329) | cdc-uscsObserved |
| 17 | Malignant MesotheliomaCancer Family | 0.7 | 0.6–0.7 | observed | #17 of 23 | USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site)) | cdc-uscsObserved |
| 18 | Malignant Thyroid Gland NeoplasmCancer | 0.5 | 0.5–0.5 | observed | #18 of 23 | USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739) | cdc-uscsObserved |
| 19 | Hodgkin LymphomaHematologic Malignancy | 0.3 | 0.3–0.3 | observed | #19 of 23 | USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal)) | cdc-uscsObserved |
| 20 | Malignant Anal NeoplasmCancer | 0.3 | 0.3–0.3 | observed | #19 of 23 | USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218) | cdc-uscsObserved |
| 21 | Malignant Salivary Gland NeoplasmCancer | 0.3 | 0.3–0.3 | observed | #19 of 23 | USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089) | cdc-uscsObserved |
| 22 | Malignant Nasopharyngeal NeoplasmCancer | 0.2 | 0.2–0.2 | observed | #22 of 23 | USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119) | cdc-uscsObserved |
| 23 | Malignant Hypopharyngeal NeoplasmCancer | 0.1 | 0.1–0.1 | observed | #23 of 23 | USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139) | cdc-uscsObserved |
cdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Top cancers
By incidence rate (age-standardized)
2015 · both sexes · all ages · 24 site groups · 2000 U.S. standard population (19 age groups)
| # | Cancer | Incidence rate (age-standardized) (per 100,000) | 95% CI | Type | Rank in scope | Site definition | Source |
|---|---|---|---|---|---|---|---|
| 1 | Malignant Breast NeoplasmCancer Family | 68.7 | 68.4–69 | observed | #1 of 24 | USCS "Male and Female Breast" (ICD-10 C50; ICD-O-3 C500-C509) | cdc-uscsObserved |
| 2 | Malignant Lung NeoplasmCancer | 60 | 59.7–60.2 | observed | #2 of 24 | USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349) | cdc-uscsObserved |
| 3 | Malignant Colon NeoplasmCancer | 28.1 | 27.9–28.3 | observed | #3 of 24 | USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260) | cdc-uscsObserved |
| 4 | Cutaneous MelanomaCancer | 23.2 | 23–23.3 | observed | #4 of 24 | USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790) | cdc-uscsObserved |
| 5 | Malignant Bladder NeoplasmCancer | 20.8 | 20.6–20.9 | observed | #5 of 24 | USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679) | cdc-uscsObserved |
| 6 | Non-Hodgkin LymphomaHematologic Malignancy | 19.9 | 19.8–20.1 | observed | #6 of 24 | USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood)) | cdc-uscsObserved |
| 7 | Malignant Kidney NeoplasmCancer | 17.4 | 17.3–17.6 | observed | #7 of 24 | USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659) | cdc-uscsObserved |
| 8 | LeukemiaCancer Family | 15.3 | 15.2–15.5 | observed | #8 of 24 | USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode) | cdc-uscsObserved |
| 9 | Malignant Thyroid Gland NeoplasmCancer | 14.8 | 14.7–15 | observed | #9 of 24 | USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739) | cdc-uscsObserved |
| 10 | Malignant Pancreatic NeoplasmCancer | 13.3 | 13.2–13.4 | observed | #10 of 24 | USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259) | cdc-uscsObserved |
| 11 | Malignant Rectal NeoplasmCancer | 11.4 | 11.3–11.5 | observed | #11 of 24 | USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209) | cdc-uscsObserved |
| 12 | Malignant Liver NeoplasmCancer | 8.8 | 8.7–8.9 | observed | #12 of 24 | USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221) | cdc-uscsObserved |
| 13 | Multiple MyelomaHematologic Malignancy | 7.4 | 7.3–7.4 | observed | #13 of 24 | USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734) | cdc-uscsObserved |
| 14 | Malignant Central Nervous System NeoplasmCancer | 6.6 | 6.5–6.7 | observed | #14 of 24 | USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729) | cdc-uscsObserved |
| 15 | Malignant Gastric NeoplasmCancer | 6.6 | 6.5–6.7 | observed | #14 of 24 | USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169) | cdc-uscsObserved |
| 16 | Malignant Esophageal NeoplasmCancer | 4.6 | 4.6–4.7 | observed | #16 of 24 | USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159) | cdc-uscsObserved |
| 17 | Malignant Laryngeal NeoplasmCancer | 3.3 | 3.2–3.3 | observed | #17 of 24 | USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329) | cdc-uscsObserved |
| 18 | Hodgkin LymphomaHematologic Malignancy | 2.7 | 2.6–2.7 | observed | #18 of 24 | USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal)) | cdc-uscsObserved |
| 19 | Malignant Anal NeoplasmCancer | 2 | 1.9–2 | observed | #19 of 24 | USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218) | cdc-uscsObserved |
| 20 | Malignant Salivary Gland NeoplasmCancer | 1.3 | 1.3–1.4 | observed | #20 of 24 | USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089) | cdc-uscsObserved |
| 21 | Malignant MesotheliomaCancer Family | 0.9 | 0.9–1 | observed | #21 of 24 | USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site)) | cdc-uscsObserved |
| 22 | Malignant Hypopharyngeal NeoplasmCancer | 0.6 | 0.6–0.6 | observed | #22 of 24 | USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139) | cdc-uscsObserved |
| 23 | Malignant Nasopharyngeal NeoplasmCancer | 0.5 | 0.5–0.6 | observed | #23 of 24 | USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119) | cdc-uscsObserved |
| 24 | Kaposi SarcomaCancer | 0.4 | 0.4–0.4 | observed | #24 of 24 | USCS "Kaposi Sarcoma" (ICD-10 C46; ICD-O-3 histology 9140 (any site)) | cdc-uscsObserved |
cdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Trend
Mortality rate (age-standardized) — top 8 cancers, all years
Top cancers of 2015 (both sexes) traced over every year published for United States. Dashed lines mark estimated or projected values; the y axis starts at zero.
cdc-uscsObservedstandard: 2000 U.S. standard population (19 age groups)264 points
Clinical research
Clinical trial activity in United States
Registrant-entered study locations on ClinicalTrials.gov mapped to this country (any study type, any phase). A site is one location; a multi-site study weighs by its number of sites. Recruiting = location status RECRUITING, or the study status when the site has none.
- Sites
- 609,712
- Studies with a site here
- 50,881
- Recruiting sites
- 71,558
- Recruiting studies
- 7,743
Computed formula ci-trial-sites-v1 · source: clinicaltrials · shares are of sites, not of studies
Data updated 18 hours agoSource updated unknowntrial_site_country_counts
Regulatory
Oncology approval records · US
Records of the country's regulator as ingested (one record = one decision for one application or product identifier). Absence of a record here is not evidence of absence.
FDA · approved: 2,343 records / 304 drugs
- Sep 18, 2026Abemaciclib approved cancer not stated in this recordEfficacy supplement 2026-09-18 (see label)openfda
- Sep 9, 2026Aminolevulinic Acid approved cancer not stated in this recordEfficacy supplement 2026-09-09 (see label)openfda
- Sep 9, 2026Sevabertinib approved cancer not stated in this recordEfficacy supplement 2026-09-09 (see label)openfda
- Sep 4, 2026Camizestrant approved Malignant Breast Neoplasmin combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor…openfda
- Aug 28, 2026Ropeginterferon Alfa-2b approved cancer not stated in this recordEfficacy supplement 2026-08-28 (see label)openfda
- Aug 25, 2026Zanidatamab approved cancer not stated in this recordEfficacy supplement 2026-08-25 (see label)openfda
- Aug 25, 2026Tislelizumab approved cancer not stated in this recordEfficacy supplement 2026-08-25 (see label)openfda
- Jul 24, 2026Enzalutamide approved cancer not stated in this recordEfficacy supplement 2026-07-24 (see label)openfda
- Jul 24, 2026Enzalutamide approved cancer not stated in this recordEfficacy supplement 2026-07-24 (see label)openfda
- Jul 14, 2026Selpercatinib approved cancer not stated in this recordEfficacy supplement 2026-07-14 (see label)openfda
Regulatory
Provenance
Sources and freshness
What each source covers for this geography, exactly as ingested. Values are normalized (units, labels) but never changed.
| Source | Metric | Sex | Years | Cancers | Estimate types | Standard population | Ingested |
|---|---|---|---|---|---|---|---|
| cdc-uscs | Incidence rate (age-standardized) | Both | 1999–2023 (25) | 24 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-uscs | Incidence rate (age-standardized) | Female | 1999–2023 (25) | 29 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-uscs | Incidence rate (age-standardized) | Male | 1999–2023 (25) | 27 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-uscs | Mortality rate (age-standardized) | Both | 1999–2024 (26) | 23 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-wonder | Mortality rate (age-standardized) | Both | 2018–2024 (7) | 36 | observed | 2000 U.S. Std. Population | 2026-09-08 |
| cdc-uscs | Mortality rate (age-standardized) | Female | 1999–2024 (26) | 28 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-wonder | Mortality rate (age-standardized) | Female | 2018–2024 (7) | 36 | observed | 2000 U.S. Std. Population | 2026-09-08 |
| cdc-uscs | Mortality rate (age-standardized) | Male | 1999–2024 (26) | 26 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-wonder | Mortality rate (age-standardized) | Male | 2018–2024 (7) | 36 | observed | 2000 U.S. Std. Population | 2026-09-08 |
| cdc-uscs | New cases | Both | 1999–2023 (25) | 32 | observed | — | 2026-09-08 |
| cdc-uscs | New cases | Female | 1999–2023 (25) | 29 | observed | — | 2026-09-08 |
| cdc-uscs | New cases | Male | 1999–2023 (25) | 27 | observed | — | 2026-09-08 |
| cdc-uscs | Deaths | Both | 1999–2024 (26) | 31 | observed | — | 2026-09-08 |
| cdc-wonder | Deaths | Both | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-uscs | Deaths | Female | 1999–2024 (26) | 28 | observed | — | 2026-09-08 |
| cdc-wonder | Deaths | Female | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-uscs | Deaths | Male | 1999–2024 (26) | 26 | observed | — | 2026-09-08 |
| cdc-wonder | Deaths | Male | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-wonder | Mortality rate (crude) | Both | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-wonder | Mortality rate (crude) | Female | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-wonder | Mortality rate (crude) | Male | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortalitylicense: approvedUS Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- CDC WONDER — Underlying Cause of Death (US mortality by ICD-10 site)license: approvedUS Government work (public domain) subject to CDC WONDER data use restrictions (statistical reporting only; counts ≤ 9 must not be published; no re-identification)
Age-standardized rates use the 2000 U.S. standard population (19 age groups); they are not comparable with rates standardized to the World (Segi) population used by IARC. Global comparisons are not available: the IARC Global Cancer Observatory remains under license review and the SEER API awaits credentials (CLAUDE.md §10.3-10.4). Only geographies with licensed observations get a page; see /countries.
Data updated 21 days agoSource updated 1999–202410,680 observations approx. · ranks from snapshots geo=USA